JP2021533789A5 - - Google Patents

Info

Publication number
JP2021533789A5
JP2021533789A5 JP2021507972A JP2021507972A JP2021533789A5 JP 2021533789 A5 JP2021533789 A5 JP 2021533789A5 JP 2021507972 A JP2021507972 A JP 2021507972A JP 2021507972 A JP2021507972 A JP 2021507972A JP 2021533789 A5 JP2021533789 A5 JP 2021533789A5
Authority
JP
Japan
Prior art keywords
cancer
virus
disease
oncolytic
virus according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046823 external-priority patent/WO2020037206A1/en
Publication of JP2021533789A publication Critical patent/JP2021533789A/ja
Publication of JP2021533789A5 publication Critical patent/JP2021533789A5/ja
Pending legal-status Critical Current

Links

JP2021507972A 2018-08-16 2019-08-16 組換え粘液腫ウイルスおよびその使用法 Pending JP2021533789A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862718990P 2018-08-16 2018-08-16
US62/718,990 2018-08-16
US201862741404P 2018-10-04 2018-10-04
US62/741,404 2018-10-04
US201862754622P 2018-11-02 2018-11-02
US62/754,622 2018-11-02
US201962813375P 2019-03-04 2019-03-04
US62/813,375 2019-03-04
PCT/US2019/046823 WO2020037206A1 (en) 2018-08-16 2019-08-16 Recombinant myxoma viruses and uses thereof

Publications (2)

Publication Number Publication Date
JP2021533789A JP2021533789A (ja) 2021-12-09
JP2021533789A5 true JP2021533789A5 (cg-RX-API-DMAC7.html) 2022-08-22

Family

ID=69525939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507972A Pending JP2021533789A (ja) 2018-08-16 2019-08-16 組換え粘液腫ウイルスおよびその使用法

Country Status (11)

Country Link
US (1) US20210196771A1 (cg-RX-API-DMAC7.html)
EP (1) EP3837354A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021533789A (cg-RX-API-DMAC7.html)
KR (1) KR20210094509A (cg-RX-API-DMAC7.html)
CN (1) CN112771157A (cg-RX-API-DMAC7.html)
AU (1) AU2019321667A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021002639A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109216A1 (cg-RX-API-DMAC7.html)
IL (1) IL280854A (cg-RX-API-DMAC7.html)
MX (1) MX2021001883A (cg-RX-API-DMAC7.html)
WO (1) WO2020037206A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
US11591616B1 (en) 2019-04-22 2023-02-28 Colorado State University Research Foundation Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC
WO2021016194A1 (en) 2019-07-19 2021-01-28 Racaniello Vincent R Second generation seneca valley virus oncolytic therapy: compositions and methods thereof
CN114615988A (zh) 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台
US20240091284A1 (en) * 2019-10-10 2024-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus comprising immunomodulatory transgenes and uses thereof
AU2021224730A1 (en) * 2020-02-20 2022-09-22 Musc Foundation For Research Development Recombinant myxoma viruses and uses thereof
JP2023548746A (ja) 2020-10-13 2023-11-21 クリヤ セラピューティクス インコーポレイテッド サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
WO2022139440A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 재조합 믹소마바이러스 및 이의 용도
WO2022159508A1 (en) * 2021-01-19 2022-07-28 Seneca Therapeutics, Inc. Armed seneca valley virus oncolytic therapy compositions and methods thereof
JP2024508920A (ja) * 2021-03-01 2024-02-28 オンコミクス セラピューティクス,インク. 多武装の粘液腫ウイルス
US20250121017A1 (en) * 2021-10-29 2025-04-17 Unm Rainforest Innovations Oncolytic virotherapy compositions and methods
KR20240157693A (ko) * 2022-03-10 2024-11-01 시티 오브 호프 세포 면역요법을 위한 막-결합 il-12
EP4624487A1 (en) * 2022-11-24 2025-10-01 Tokushima University Production of antibodies against protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2023954B1 (en) * 2006-05-19 2013-07-17 Sanofi Pasteur, Inc. Immunological composition
WO2008070367A2 (en) * 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
FR2946536B1 (fr) * 2009-06-11 2011-07-29 Agronomique Inst Nat Rech Utilisation d'une souche attenuee de myxoma virus comme oncolytique
DK3552615T3 (da) * 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
PL3368572T5 (pl) * 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
SI3368683T1 (sl) * 2015-10-27 2020-07-31 Pharmassist Ltd Postopek za kvantifikacijo PD-L1
TW201825511A (zh) * 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒

Similar Documents

Publication Publication Date Title
O'Bryan et al. Oncolytic virotherapy for breast cancer treatment
Shi et al. Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment
Chen et al. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects
WO2020037206A4 (en) Recombinant myxoma viruses and uses thereof
JP6794442B2 (ja) 新規な遺伝子組換えワクシニアウイルス
Dong et al. Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
US20220056480A1 (en) Modified orthopoxvirus vectors
US20240132913A1 (en) Modified orthopoxvirus vectors
O’Leary et al. Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose
Li et al. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
BR112019013215A2 (pt) vírus oncolítico, composição farmacêutica, produto de fabricação, método para tratar câncer e uso
JP2021527694A5 (cg-RX-API-DMAC7.html)
JP7754891B2 (ja) Ccl21をコードする組換えラブドウイルス
Chaurasiya et al. Viroimmunotherapy for breast cancer: Promises, problems and future directions
Huang et al. Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses
JP2022536929A5 (cg-RX-API-DMAC7.html)
JP2018510158A (ja) 抗体組み合わせを用いるウイルス療法
JP7842751B2 (ja) 腫瘍溶解性ウイルスが有効なtil療法のためにt細胞応答を強化する
BR112021001117A2 (pt) células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas
WO2020067085A1 (ja) 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬
CN110564767A (zh) 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法
Ekeke et al. Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies: CN Ekeke et al.
TWI817159B (zh) 重組牛痘病毒
Akunne et al. Emerging strategies in cancer immunotherapy: Expanding horizons and future perspectives
JP2023552289A5 (cg-RX-API-DMAC7.html)